These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34295186)

  • 1. Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies.
    Camilleri M; Hale M; Morlion B; Tack J; Webster L; Wild J
    J Pain Res; 2021; 14():2179-2189. PubMed ID: 34295186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing Minimal Clinically Important Differences in Quality of Life Measures in Opioid-Induced Constipation.
    Tack J; Camilleri M; Hale M; Morlion B; Nalamachu S; Webster L; Wild J
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):855-863. PubMed ID: 33965574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer.
    Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
    Ann Oncol; 2018 Jun; 29(6):1461-1467. PubMed ID: 32151367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies.
    Saito Y; Yokota T; Arai M; Tada Y; Sumitani M
    J Pain Res; 2019; 12():127-138. PubMed ID: 30613161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
    Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
    Wild J; Webster L; Yamada T; Hale M
    Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy.
    Webster LR; Hale ME; Yamada T; Wild JE
    J Pain Res; 2020; 13():605-612. PubMed ID: 32280263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
    Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
    J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between health-related quality of life and symptoms in patients with chronic constipation: an integrated analysis of three phase 3 trials of prucalopride.
    Tack J; Camilleri M; Dubois D; Vandeplassche L; Joseph A; Kerstens R
    Neurogastroenterol Motil; 2015 Mar; 27(3):397-405. PubMed ID: 25581251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials.
    Wild J; Yamada T; Arjona Ferreira JC; Hale M
    Pain; 2019 Oct; 160(10):2358-2364. PubMed ID: 31145214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial.
    Marciniak CM; Toledo S; Lee J; Jesselson M; Bateman J; Grover B; Tierny J
    World J Gastroenterol; 2014 Nov; 20(43):16323-33. PubMed ID: 25473191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translating Clinical Findings into the Patient's Perspective: Post-hoc Pooled Analysis of Bowel Movement Changes as a Predictor of Improvement in Patients' Opioid-induced Constipation Symptoms and Outcomes.
    Coyne KS; Poon JL; Thompson C; Hu Y; Datto CJ; Sostek M
    Clin Ther; 2017 Jan; 39(1):75-88. PubMed ID: 27938897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients' Self-Assessment of the Symptoms and Impact of Opioid-Induced Constipation: Results From a Prospective Observational Cohort Study of Japanese Patients With Cancer.
    Fumita S; Imai H; Harada T; Noriyuki T; Gamoh M; Akashi Y; Sato H; Kizawa Y; Tokoro A
    J Pain Symptom Manage; 2020 May; 59(5):1043-1051.e2. PubMed ID: 31805362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain.
    Slappendel R; Simpson K; Dubois D; Keininger DL
    Eur J Pain; 2006 Apr; 10(3):209-17. PubMed ID: 15914049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives.
    Hale ME; Wild JE; Yamada T; Yokota T; Tack J; Andresen V; Drewes AM
    Therap Adv Gastroenterol; 2021; 14():17562848211032320. PubMed ID: 34377150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
    Hamano J; Higashibata T; Kessoku T; Kajiura S; Hirakawa M; Oyamada S; Ariyoshi K; Yamada T; Yamamoto Y; Takashima Y; Doki K; Homma M; Mathis BJ; Jono T; Ogata T; Tanaka K; Kasai Y; Iwaki M; Fuyuki A; Nakajima A; Hayashi R; Ando T; Izawa N; Kobayashi Y; Horie Y; Morita T
    J Clin Oncol; 2024 Dec; 42(35):4206-4217. PubMed ID: 39255425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy.
    Stern EK; Brenner DM
    J Pain Res; 2018; 11():195-199. PubMed ID: 29391826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: a retrospective analysis.
    Nishiba H; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Mogi J; Obayashi K; Minato K
    Ann Palliat Med; 2023 Jul; 12(4):697-707. PubMed ID: 37081703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study.
    Cobo Dols M; Beato Zambrano C; Cabezón-Gutiérrez L; Chicas-Sett R; Blancas López-Barajas MI; García Navalón FJ; Fírvida Pérez JL; Serrano Bermúdez G; Togores Torres P; Delgado Mingorance I; Giraldo Marín A; Librán Oriol A; Paredes Lario A; Sánchez Mauriño P; Higuera Gómez O; Moreno Muñoz D; Huerta González I; Sanz-Yagüe A; Soler López B
    BMJ Support Palliat Care; 2023 Dec; 13(e2):e318-e326. PubMed ID: 33707299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of constipation on opioid therapy management among long-term opioid users, based on a patient survey.
    Gupta S; Patel H; Scopel J; Mody RR
    J Opioid Manag; 2015; 11(4):325-38. PubMed ID: 26312960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.